REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY-Reference-Cited by-同舟云学术

REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY

Published:2020-08 Issue:8 Volume:40 Page:1529-1539
ISSN:0275-004X
Container-title:Retina
language:en
Short-container-title:

Author:

Koh Adrian,Lai Timothy Y.Y.,Wei Wen Bin,Mori Ryusaburo,Wakiyama Harumi,Park Kyu Hyung,Ngah Fariza,Macfadden Wayne,Dunger-Baldauf Cornelia,Parikh Soumil

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology,General Medicine

Reference37 articles.

1. Improved specificity of polypoidal choroidal vasculopathy diagnosis using a modified EVEREST criteria;Cheung;Retina,2015

2. Idiopathic polypoidal choroidal vasculopathy (IPCV);Yannuzzi;Retina,1990

3. Polypoidal choroidal vasculopathy: clinical features and genetic predisposition;Honda;Ophthalmologica,2014

4. Do we need a new classification for choroidal neovascularization in age-related macular degeneration?;Freund;Retina,2010

5. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment;Koh;Retina,2013

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aflibercept monotherapy or bevacizumab first for diabetic macular edema;Indian Journal of Ophthalmology;2024-01-25

2. Factors Influencing Visual Acuity in Patients with Active Subfoveal Circumscribed Polypoidal Choroidal Vasculopathy and Changes in Imaging Parameters;Diagnostics;2023-09-21

3. Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials;Graefe's Archive for Clinical and Experimental Ophthalmology;2023-06-09

4. Factors influencing visual acuity in patients with active polypoidal choroidal vasculopathy and imaging parameters changes;2023-03-21

5. The comparison of two different strategies of intravitreal conbercept for polypoidal choroidal vasculopathy in Chinese patients results from a 48‐week randomized phase 4 study: STAR study;Acta Ophthalmologica;2022-10-18